Sec Form 13G Filing - ATHOS KG @ BioNTech SE

Sec Form 13G Filing - ATHOS KG filing for BioNTech SE (BNTX) - 2020-02-12

Insider filing report for Changes in Beneficial Ownership

Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.

"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. )*

BIONTECH SE

(Name of Issuer)

Ordinary Shares, no par value per share (€1.00 nominal amount)

(including Ordinary Shares represented by American Depositary Shares)

(Title of Class of Securities)

09075V102**

(CUSIP Number)

October 9, 2019

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

**	This CUSIP number applies to the American Depositary Shares (“ADSs”) of the Issuer, which are quoted on the Nasdaq Global Select Market under the symbol “BNTX.” Each ADS represents one Ordinary Share. No CUSIP has been assigned to the Ordinary Shares.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13G

CUSIP No. 09075V102

SCHEDULE 13G

CUSIP No. 09075V102

SCHEDULE 13G

CUSIP No. 09075V102

SCHEDULE 13G

CUSIP No. 09075V102

Item 1(a)

Name of Issuer.

The name of the issuer is BioNTech SE (the “Company”).

Item 1(b)

Address of Issuer’s Principal Executive Offices.

The Company’s principal executive office is located at An der Goldgrube 12, D-55131 Mainz, Germany.

Item 2(a)

Name of Person Filing.

This Schedule 13G is being jointly filed by ATHOS KG, AT Impf GmbH, Helmut Jeggle and Thomas Maier, each of the foregoing, a “Reporting Person,” and collectively, the “Reporting Persons”. The sole member of AT Impf GmbH is ATHOS KG and, as a result, ATHOS KG is deemed to be the beneficial owner of the securities held by AT Impf GmbH. Helmut Jeggle and Thomas Maier are each general partners (komplementär) of ATHOS KG. The limited partners (kommanditisten) of ATHOS KG are members of the families of Thomas and Andreas Strüngmann.

The Reporting Persons have entered into a Joint Filing Agreement, dated February 12, 2020, a copy of which is incorporated by reference herein to Exhibit on the Schedule 13G filed on February 12, 2020, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.

Item 2(b)

Address of Principal Business Office or, if none, Residence.

The address of the principal business office of each of the Reporting Persons is Bergfeldstraße 9 83607 Holzkirchen.

Item 2(c)

Citizenship.

ATHOS KG is a German limited partnership (Kommanditgesellschaft); AT Impf GmbH is a German limited liability company (Gesellschaft mit beschränkter Haftung); and Mr. Jeggle and Mr. Maier are each citizens of Germany.

Item 2(d)

Title of Class of Securities.

Ordinary Shares, no par value per share (€1.00 nominal amount)

Item 2(e)

CUSIP No.

09075V102 (This CUSIP number applies to the American Depositary Shares (“ADSs”) of the Issuer, which are quoted on the Nasdaq Global Select Market under the symbol “BNTX.” Each ADS represents one Ordinary Share. No CUSIP has been assigned to the Ordinary Shares.)

Item 3

If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b), check whether the person filing is a:

Not applicable.

Item 4

Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the

issuer identified in Item 1.

(a)

Amount beneficially owned:

See the responses to Item 9 on the attached cover pages

(b)

Percent of class:

See the responses to Item 11 on the attached cover pages

(c)

Number of shares as to which such person has:

(i)

Sole power to vote or direct the vote: See the responses to Item 5 on the attached cover pages

(ii)

Shared power to vote or direct the vote: See the responses to Item 6 on the attached cover pages

(iii)

Sole power to dispose or direct the disposition: See the responses to Item 7 on the attached cover pages

(iv)

Shared power to dispose or direct the disposition: See the responses to Item 8 on the attached cover pages

Item 5

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof each of the Reporting Persons has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

Item 6

Ownership of More Than Five Percent on Behalf of Another Person.

See responses to Item 2(a) and Item 4.

Item 7

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

See responses to Item 2(a) and Item 4.

Item 8

Identification and Classification of Members of the Group.

Not applicable.

Item 9

Notice of Dissolution of Group.

Not applicable.

Item 10

Certification.

Not Applicable.

SIGNATURE

After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.


Date: February 12, 2020	ATHOS KG

	By:	/s/ Thomas Maier /s/ Helmut Jeggle
	Name: Thomas Maier Helmut Jeggle
	Title: Authorized Signatory

Date: February 12, 2020	AT IMPF GMBH

	By:	/s/ Thomas Maier /s/ Helmut Jeggle
	Name: Thomas Maier Helmut Jeggle
	Title: Authorized Signatory

Date: February 12, 2020	HELMUT JEGGLE

	/s/ Helmut Jeggle

Date: February 12, 2020	THOMAS MAIER

	/s/ Thomas Maier

EXHIBIT 1

JOINT FILING AGREEMENT

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.


Date: February 12, 2020	ATHOS KG

	By:	/s/ Thomas Maier /s/ Helmut Jeggle_
	Name: Thomas Maier Helmut Jeggle
	Title: Authorized Signatory

Date: February 12, 2020	AT IMPF GMBH

	By:	/s/ Thomas Maier /s/ Helmut Jeggle
	Name: Thomas Maier Helmut Jeggle
	Title: Authorized Signatory

Date: February 12, 2020	HELMUT JEGGLE

	/s/ Helmut Jeggle

Date: February 12, 2020	THOMAS MAIER

	/s/ Thomas Maier

NAME OF REPORTING PERSONS

ATHOS KG

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

(a) ☐ (b) ☐

SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

Germany